DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Parkinson’s Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

Key Takeaways from the Parkinson’s Disease Pipeline Report

• On May 29, 2026- Biogen announced a study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study.
• On May 28, 2026- Gateway Institute for Brain Research initiated a phase II study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson’s Disease compared to placebo.
• On May 27, 2026- Denali Therapeutics Inc. conducted a Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson’s Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
• On May 27, 2026- Intra-Cellular Therapies Inc. initiated a study in patients with a diagnosis of Parkinson’s Disease consistent with the UK Parkinson’s Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
• On May 26, 2026- Glaceum announced a phase 2a study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups – 1 group receiving a placebo – in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin.
• On May 11, 2026- Hillhurst Biopharmaceuticals Inc. initiated a phase 2a study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson’s disease (PD).
• DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 150+ active players working to develop 200+ pipeline therapies for Parkinson’s Disease treatment.
• The Parkinson’s Disease Companies such as Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.
• Promising Parkinson’s Disease Pipeline Therapies such as KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others.

Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Parkinson’s Disease Clinical Trials Assessment

The Parkinson’s Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Parkinson’s Disease Pipeline Report also highlights the unmet needs with respect to the Parkinson’s Disease.

Parkinson’s Disease Overview

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement and coordination. It results from the gradual loss of dopamine-producing neurons in the brain, leading to characteristic motor and non-motor symptoms. The disease typically develops in older adults and progresses slowly, with symptoms worsening over time. Although not curable, available treatments can effectively manage symptoms and improve quality of life. Parkinson’s disease is caused by a combination of genetic and environmental factors that lead to progressive neuronal damage. Advancing age is the strongest risk factor, while inherited mutations in genes such as SNCA, LRRK2, PARK2, PINK1, and DJ-1 contribute to familial forms of the disease. Environmental exposures, including pesticides, heavy metals, and other neurotoxins, are also implicated in increasing disease risk.

Parkinson’s Disease Emerging Drugs Profile

• Prasinezumab: Roche/Prothena Biosciences

Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. The safety database for prasinezumab consists of data from more than 900 Parkinson’s disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. The drug is currently in Phase III of its clinical development for the treatment of patients with Parkinson’s disease.

• Buntanetap: Annovis Bio

Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. The drug is currently in Phase III stage of its clinical development for the treatment of patients with Parkinson’s disease.

• NEU 411: Neuron23

NEU‑411 is an orally available, brain-penetrant small-molecule inhibitor of the kinase LRRK2, being developed by Neuron23, Inc. for Parkinson’s disease. It is designed for the subset of patients with LRRK2-driven PD whether through LRRK2 mutations or predictive SNPs where over activity of LRRK2 is believed to contribute to disease progression. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Parkinson’s disease.

• VTX3232: Ventyx Biosciences

VTX3232 is an oral, brain-penetrant inhibitor of the NLRP3 inflammasome, developed to target neuroinflammation in Parkinson’s disease by reducing harmful signaling from microglial activation. It crosses the blood–brain barrier, maintains plasma and cerebrospinal fluid concentrations above the inhibitory threshold for NLRP3, and thereby aims to not only ease motor/non-motor symptoms but modify underlying disease progression. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson’s disease

• ANPD001: Aspen Neuroscience

ANPD001, developed by Aspen Neuroscience, is an investigational autologous cell-therapy for Parkinson’s disease that uses a patient’s own skin cells reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into dopaminergic neuronal precursor cells (DANPCs) for implantation. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Parkinson’s disease.

• Lu AF28996: Lundbeck

Lu AF28996 is an investigational small-molecule therapy developed by H. Lundbeck A/S for the treatment of Parkinson’s disease. It is designed as a dual dopamine D1 and D2 receptor agonist, providing concerted stimulation of both receptor subtypes to restore dopaminergic signaling and improve motor control in patients with Parkinson’s disease. This mechanism of action aims to compensate for dopamine deficiency in the nigrostriatal pathway, thereby alleviating motor symptoms such as bradykinesia and rigidity. Lu AF28996 is formulated for oral administration, typically delivered as a capsule taken once daily. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson’s disease

Learn more about Parkinson’s Disease Drugs opportunities in our groundbreaking Research and Development projects @ Parkinson’s Disease Unmet Needs

The Parkinson’s Disease Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
• Parkinson’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

Parkinson’s Disease Companies

Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Parkinson’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Parkinson’s Disease Pipeline Report

• Coverage– Global
• Parkinson’s Disease Companies– Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc., Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics and others.
• Parkinson’s Disease Pipeline Therapies- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
• Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Parkinson’s Disease Pipeline on our website @ Parkinson’s Disease Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Parkinson’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson’s Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Prasinezumab: Roche/ Prothena Biosciences
9. Mid Stage Products (Phase II)
10. NEU 411: Neuron23
11. Early Stage Products (Phase I)
12. Lu AF28996: Lundbeck
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Parkinson’s Disease Key Companies
16. Parkinson’s Disease Key Products
17. Parkinson’s Disease- Unmet Needs
18. Parkinson’s Disease- Market Drivers and Barriers
19. Parkinson’s Disease- Future Perspectives and Conclusion
20. Parkinson’s Disease Analyst Views
21. Parkinson’s Disease Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights